S. T. Kim

490 total citations
16 papers, 373 citations indexed

About

S. T. Kim is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Economics and Econometrics. According to data from OpenAlex, S. T. Kim has authored 16 papers receiving a total of 373 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 11 papers in Cancer Research and 4 papers in Economics and Econometrics. Recurrent topics in S. T. Kim's work include Cancer Genomics and Diagnostics (11 papers), Renal cell carcinoma treatment (11 papers) and Economic and Financial Impacts of Cancer (4 papers). S. T. Kim is often cited by papers focused on Cancer Genomics and Diagnostics (11 papers), Renal cell carcinoma treatment (11 papers) and Economic and Financial Impacts of Cancer (4 papers). S. T. Kim collaborates with scholars based in United States, South Korea and France. S. T. Kim's co-authors include Robert J. Motzer, M. Dror Michaelson, Ronald M. Bukowski, Charles M. Baum, Robert A. Figlin, G. R. Hudes, George Wilding, Bruce G. Redman, Thomas E. Hutson and Brian I. Rini and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and PubMed.

In The Last Decade

S. T. Kim

16 papers receiving 364 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S. T. Kim United States 8 296 252 190 115 20 16 373
S. Négrier France 6 327 1.1× 261 1.0× 210 1.1× 89 0.8× 15 0.8× 9 373
U.P. Strauss Germany 10 319 1.1× 224 0.9× 139 0.7× 238 2.1× 28 1.4× 14 505
Mohamad Khasawneh United States 6 223 0.8× 181 0.7× 106 0.6× 93 0.8× 25 1.3× 8 333
J.-L. Lee South Korea 8 215 0.7× 129 0.5× 91 0.5× 137 1.2× 94 4.7× 11 339
Ki Sun Jung South Korea 10 153 0.5× 201 0.8× 82 0.4× 146 1.3× 39 1.9× 21 347
B. Escudier France 9 221 0.7× 189 0.8× 120 0.6× 94 0.8× 48 2.4× 41 327
K. Burock United States 9 155 0.5× 136 0.5× 105 0.6× 55 0.5× 12 0.6× 21 250
Zita Dubauskas Lim United States 8 615 2.1× 512 2.0× 329 1.7× 173 1.5× 64 3.2× 23 686
Chirag Amin United States 6 210 0.7× 195 0.8× 123 0.6× 42 0.4× 41 2.0× 17 309

Countries citing papers authored by S. T. Kim

Since Specialization
Citations

This map shows the geographic impact of S. T. Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. T. Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. T. Kim more than expected).

Fields of papers citing papers by S. T. Kim

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. T. Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. T. Kim. The network helps show where S. T. Kim may publish in the future.

Co-authorship network of co-authors of S. T. Kim

This figure shows the co-authorship network connecting the top 25 collaborators of S. T. Kim. A scholar is included among the top collaborators of S. T. Kim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. T. Kim. S. T. Kim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Finn, Richard S., John Crown, István Láng, et al.. (2013). Phase II Study of Palbociclib (PD-0332991) + Letrozole vs Letrozole Alone in First-Line ER + /HER2- Advanced Breast Cancer. Annals of Oncology. 24. ix32–ix32. 5 indexed citations
2.
3.
Heath, Elisabeth I., G. R. Blumenschein, Roger B. Cohen, et al.. (2009). Sunitinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors: Updated phase I study results. Journal of Clinical Oncology. 27(15_suppl). e14509–e14509. 3 indexed citations
4.
Figlin, Robert A., Thomas E. Hutson, M. Dror Michaelson, et al.. (2009). Prognostic factors for overall survival with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology. 27(15_suppl). 5042–5042. 12 indexed citations
5.
Cella, David, M. Dror Michaelson, Joseph C. Cappelleri, et al.. (2009). Quality of life (QOL) with sunitinib versus interferon-alfa (IFN-α) as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): Final results. Journal of Clinical Oncology. 27(15_suppl). 6529–6529. 3 indexed citations
6.
Heath, Elisabeth I., G. R. Blumenschein, Roger B. Cohen, et al.. (2008). Phase I study of sunitinib in combination with carboplatin (C) plus paclitaxel (P) in patients (pts) with advanced solid tumors (STs). Journal of Clinical Oncology. 26(15_suppl). 3565–3565. 2 indexed citations
7.
Patel, Premal H., G. Varuni Kondagunta, Bruce G. Redman, et al.. (2007). Phase I/II study of sunitinib malate in combination with gefitinib in patients (pts) with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology. 25(18_suppl). 5097–5097. 6 indexed citations
8.
Motzer, Robert J., Robert A. Figlin, Thomas E. Hutson, et al.. (2007). Sunitinib versus interferon-alfa (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC): Updated results and analysis of prognostic factors. Journal of Clinical Oncology. 25(18_suppl). 5024–5024. 71 indexed citations
9.
Cella, David, J.C. Cappelleri, Andrew G. Bushmakin, et al.. (2007). Quality of life (QOL) predicts for progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib compared to interferon-alpha (IFN-α). Journal of Clinical Oncology. 25(18_suppl). 6594–6594. 6 indexed citations
10.
Rosenberg, Jonathan E., Robert J. Motzer, M. Dror Michaelson, et al.. (2007). Sunitinib therapy for patients (pts) with metastatic renal cell carcinoma (mRCC): Updated results of two phase II trials and prognostic factor analysis for survival. Journal of Clinical Oncology. 25(18_suppl). 5095–5095. 23 indexed citations
11.
Motzer, Robert J., Thomas E. Hutson, Piotr Tomczak, et al.. (2006). Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology. 24(18_suppl). LBA3–LBA3. 69 indexed citations
12.
Ronnen, Ellen A., G. Varuni Kondagunta, Christopher Lau, et al.. (2006). A phase I study of sunitinib malate (SU11248) in combination with gefitinib in patients with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology. 24(18_suppl). 4537–4537. 10 indexed citations
13.
Motzer, Robert J., Brian I. Rini, M. Dror Michaelson, et al.. (2005). Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC). Journal of Clinical Oncology. 23(16_suppl). 4508–4508. 82 indexed citations
14.
Motzer, Robert J., Brian I. Rini, M. Dror Michaelson, et al.. (2004). SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: Results of a phase 2 trial. Journal of Clinical Oncology. 22(14_suppl). 4500–4500. 15 indexed citations
15.
Motzer, Robert J., Brian I. Rini, M. Dror Michaelson, et al.. (2004). SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: Results of a phase 2 trial. Journal of Clinical Oncology. 22(14_suppl). 4500–4500. 55 indexed citations
16.
Kim, S. T., et al.. (1992). Quality of life of ESRD patients: development of a tool and comparison between transplant and dialysis patients.. PubMed. 24(4). 1435–7. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by S. Négrier Breakdown of academic impact, for papers by U.P. Strauss Breakdown of academic impact, for papers by Mohamad Khasawneh Breakdown of academic impact, for papers by J.-L. Lee Breakdown of academic impact, for papers by Ki Sun Jung Breakdown of academic impact, for papers by B. Escudier Breakdown of academic impact, for papers by K. Burock Breakdown of academic impact, for papers by Zita Dubauskas Lim Breakdown of academic impact, for papers by Chirag Amin
Rankless by CCL
2026